Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Emily Bergsland, MD
Headshot of Emily Bergsland
Emily Bergsland

Description

Summary

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Details

Keywords

Pancreatic Neuroendocrine Neoplasm, Genetic Assay, Biomarkers, Neoplasms, Neuroendocrine Tumors, Islet Cell Adenoma, Disease Susceptibility, Genetic Predisposition to Disease, Hereditary Cancer Panel

Eligibility

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States
  • Univeristy of California, San Diego accepting new patients
    San Diego California 92093 United States

Lead Scientist at UCSF

  • Emily Bergsland, MD
    Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05746182
Study Type
Observational
Participants
Expecting 300 study participants
Last Updated